Login / Signup

Transcatheter Arterial Chemoembolization with Drug-Eluting Beads for the Treatment of Hepatocellular Carcinoma: Recommended Selection for Small-Caliber (<100 μm) Beads.

Wei-Chou ChangHsian-He HsuSung-Hua ChiuWen-Yen HuangCheng-Hsiang LoHsuan-Hwai LinPei-Ching HuangYu-Lueng ShihYung Liang Wan
Published in: Journal of hepatocellular carcinoma (2021)
Drug-eluting beads transarterial chemoembolization (DEB-TACE) is an alternative to conventional lipiodol-based TACE (cTACE) to treat hepatocellular carcinoma (HCC). With the advancement in pharmacology, small-caliber DEB-TACE (<100 μm) has been introduced since 2016. For the treatment of hepatic neoplasms or HCC, there is a tendency to use smaller beads by DEB-TACE to achieve more extensive tumor necrosis and a significant reduction in liver toxicity in comparison with that caused by cTACE. However, the indications and potential complications of small-caliber DEB-TACE remain uncertain and have not been well established, due to lack of randomized phase III clinical trials. Instead of systematic or meta-analysis review, this narrative review article describes the suggested indications and contraindications of DEB-TACE with small DEBs, benefit of super-selective embolization of the feeding arteries and the recommended selection of small-caliber DEB. This review was approved by the institutional review board (File Number: 1-105-05-158).
Keyphrases
  • phase iii
  • clinical trial
  • open label
  • systematic review
  • double blind
  • placebo controlled
  • radiofrequency ablation
  • oxidative stress
  • combination therapy
  • study protocol
  • replacement therapy